Sirtuin 6 regulates the proliferation and survival of clear cell renal cell carcinoma cells via B‑cell lymphoma 2

An,Jun; Yang,Jieping; Yao,Yang; Lu,Kaining; Zhao,Zhiqiang; Yu,Meng; Zhu,Yuyan

doi:10.3892/ol.2021.12554

Sirtuin 6 regulates the proliferation and survival of clear cell renal cell carcinoma cells via B‑cell lymphoma 2

Authors:
- Jun An
- Jieping Yang
- Yang Yao
- Kaining Lu
- Zhiqiang Zhao
- Meng Yu
- Yuyan Zhu
View Affiliations

Affiliations: Department of Urology, The First Hospital of China Medical University, Shenyang, Liaoning 110001, P.R. China, Department of Physiology, Shenyang Medical College, Shenyang, Liaoning 110034, P.R. China, Department of Urology and Nephrology, Ningbo First Hospital, The Affiliated Hospital of Zhejiang University, Ningbo, Zhejiang 315010, P.R. China, Department of Intensive Care Unit, Mudanjiang Forestry Center Hospital, Mudanjiang, Heilongjiang 157000, P.R. China, Key Laboratory of Transgenic Animal Research, Department of Laboratory Animal Science, China Medical University, Shenyang, Liaoning 110122, P.R. China
Published online on: February 17, 2021 https://doi.org/10.3892/ol.2021.12554
Article Number: 293
Copyright: © An et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Sirtuin 6 (SIRT6) is a member of the third family of longevity proteins (SIRTs) that is involved in the development of different types of cancer. However, the potential role of SIRT6 in clear cell renal cell carcinoma (ccRCC) and its molecular mechanism have not yet been fully elucidated. Therefore, the present study aimed to investigate the association between SIRT6 and ccRCC, and to further examine the underlying mechanism of its effect on ccRCC proliferation, using bioinformatics analysis, and in vitro and in vivo experiments. The results of the present study demonstrated that SIRT6 was upregulated in ccRCC tissues. In addition, bioinformatics analysis revealed that high SIRT6 expression was closely associated with poor prognosis of patients with ccRCC. In vitro experiments demonstrated that silencing SIRT6 expression in ccRCC‑derived 769‑P and 786‑O cells significantly inhibited their proliferation, migration and invasion. Consistent with these results, in vivo assays demonstrated that SIRT6 knockdown markedly attenuated tumor growth arising from 769‑P cells. Furthermore, depletion of SIRT6 enhanced the sensitivity of ccRCC cells to cisplatin. Notably, silencing SIRT6 expression decreased B‑cell lymphoma 2 (Bcl‑2) expression and increased Bax expression, respectively. Taken together, these results suggest that SIRT6 acts as a proto‑oncogene in ccRCC through the augmentation of the Bcl‑2‑dependent pro‑survival pathway, and may be used as a therapeutic target for patients with ccRCC.

View Figures

View References

1	Hsieh JJ, Purdue MP, Signoretti S, Swanton C, Albiges L, Schmidinger M, Heng DY, Larkin J and Ficarra V: Renal cell carcinoma. Nat Rev Dis Primers. 3:170092017. View Article : Google Scholar : PubMed/NCBI
2	Gray R, Hentschke R, Isaac S, Mead R, Ozturk A, Rieley P, Smale K and Stern R: Sampling variation of reported results. Nature. 234:230–231. 1971. View Article : Google Scholar : PubMed/NCBI
3	Chen YL, Ge GJ, Qi C, Wang H, Wang HL, Li LY, Li GH and Xia LQ: A five-gene signature may predict sunitinib sensitivity and serve as prognostic biomarkers for renal cell carcinoma. J Cell Physiol. 233:6649–6660. 2018. View Article : Google Scholar : PubMed/NCBI
4	Escudier B, Porta C, Schmidinger M, Rioux-Leclercq N, Bex A, Khoo V, Gruenvald V and Horwich A: Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 27:v58–v68. 2016. View Article : Google Scholar : PubMed/NCBI
5	Lam JS, Shvarts O, Leppert JT, Pantuck AJ, Figlin RA and Belldegrun AS: Postoperative surveillance protocol for patients with localized and locally advanced renal cell carcinoma based on a validated prognostic nomogram and risk group stratification system. J Urol. 174:466–472. 2005. View Article : Google Scholar : PubMed/NCBI
6	Wang Y, He J, Liao M, Hu M, Li W, Ouyang H, Wang X, Ye T, Zhang Y and Ouyang L: An overview of Sirtuins as potential therapeutic target: Structure, function and modulators. Eur J Med Chem. 161:48–77. 2019. View Article : Google Scholar : PubMed/NCBI
7	Haigis MC and Sinclair DA: Mammalian sirtuins: Biological insights and disease relevance. Ann Rev Pathol. 5:253–295. 2010. View Article : Google Scholar
8	Sebastián C, Zwaans BM, Silberman DM, Gymrek M, Goren A, Zhong L, Ram O, Truelove J, Guimaraes AR, Toiber D, et al: The histone deacetylase SIRT6 is a tumor suppressor that controls cancer metabolism. Cell. 151:1185–1199. 2012. View Article : Google Scholar : PubMed/NCBI
9	Marquardt JU, Fischer K, Baus K, Kashyap A, Ma S, Krupp M, Linke M, Teufel A, Zechner U, Strand D, et al: Sirtuin-6-dependent genetic and epigenetic alterations are associated with poor clinical outcome in hepatocellular carcinoma patients. Hepatology. 58:1054–1064. 2013. View Article : Google Scholar : PubMed/NCBI
10	Zhang C, Yu Y, Huang Q and Tang K: SIRT6 regulates the proliferation and apoptosis of hepatocellular carcinoma via the ERK1/2 signaling pathway. Mol Med Rep. 20:1575–1582. 2019.PubMed/NCBI
11	Han Z, Liu L, Liu Y and Li S: Sirtuin SIRT6 suppresses cell proliferation through inhibition of Twist1 expression in non-small cell lung cancer. Int J Clin Exp Pathol. 7:4774–4781. 2014.PubMed/NCBI
12	Khongkow M, Olmos Y, Gong C, Gomes AR, Monteiro LJ, Yagüe E, Cavaco TB, Khongkow P, Man EP, Laohasinnarong S, et al: SIRT6 modulates paclitaxel and epirubicin resistance and survival in breast cancer. Carcinogenesis. 34:1476–1486. 2013. View Article : Google Scholar : PubMed/NCBI
13	Qi W, Fitchev PS, Cornwell ML, Greenberg J, Cabe M, Weber CR, Roy HK, Crawford SE and Savkovic SD: FOXO3 growth inhibition of colonic cells is dependent on intraepithelial lipid droplet density. J Biol Chem. 288:16274–16281. 2013. View Article : Google Scholar : PubMed/NCBI
14	Colas E, Perez C, Cabrera S, Pedrola N, Monge M, Castellvi J, Eyzaguirre F, Gregorio J, Ruiz A, Llaurado M, et al: Molecular markers of endometrial carcinoma detected in uterine aspirates. Int J Cancer. 129:2435–2444. 2011. View Article : Google Scholar : PubMed/NCBI
15	Liu Y, Xie QR, Wang B, Shao J, Zhang T, Liu T, Huang G and Xia W: Inhibition of SIRT6 in prostate cancer reduces cell viability and increases sensitivity to chemotherapeutics. Protein Cell. 4:702–710. 2013. View Article : Google Scholar : PubMed/NCBI
16	Desantis V, Lamanuzzi A and Vacca A: The role of SIRT6 in tumors. Haematologica. 103:1–4. 2018. View Article : Google Scholar : PubMed/NCBI
17	Tao NN, Ren JH, Tang H, Ran LK, Zhou HZ, Liu B, Huang AL and Chen J: Deacetylation of Ku70 by SIRT6 attenuates Bax-mediated apoptosis in hepatocellular carcinoma. Biochem Biophys Res Commun. 485:713–719. 2017. View Article : Google Scholar : PubMed/NCBI
18	Amin MB, Edge S, Greene F, Byrd DR, Brookland RK, Washington MK, Gershenwald JE, Compton CC, Hess KR, Sullivan DC, et al: AJCC cancer staging manual. (8th edition). Springer International Publishing; pp. 739–747. 2017
19	World Medical Association: World medical association declaration of Helsinki: Ethical principles for medical research involving human subjects. JAMA. 310:2191–2194. 2013. View Article : Google Scholar : PubMed/NCBI
20	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
21	Kugel S, Sebastián C, Fitamant J, Ross KN, Saha SK, Jain E, Gladden A, Arora KS, Kato Y, Rivera MN, et al: SIRT6 suppresses pancreatic cancer through control of Lin28b. Cell. 165:1401–1415. 2016. View Article : Google Scholar : PubMed/NCBI
22	Ming M, Han W, Zhao B, Sundaresan NR, Deng CX, Gupta MP and He YY: SIRT6 promotes COX-2 expression and acts as an oncogene in skin cancer. Cancer Res. 74:5925–5933. 2014. View Article : Google Scholar : PubMed/NCBI
23	Bauer I, Grozio A, Lasigliè D, Basile G, Sturla L, Magnone M, Sociali G, Soncini D, Caffa I, Poggi A, et al: The NAD+-dependent histone deacetylase SIRT6 promotes cytokine production and migration in pancreatic cancer cells by regulating Ca²⁺ responses. J Biol Chemistry. 287:40924–40937. 2012. View Article : Google Scholar
24	Khongkow P, Gomes AR, Gong C, Man EP, Tsang JW, Zhao F, Monteiro LJ, Coombes RC, Medema RH, Khoo US and Lam EW: Paclitaxel targets FOXM1 to regulate KIF20A in mitotic catastrophe and breast cancer paclitaxel resistance. Oncogene. 35:990–1002. 2016. View Article : Google Scholar : PubMed/NCBI
25	Prestayko AW, D'Aoust JC, Issell BF and Crooke ST: Cisplatin (cis-diamminedichloroplatinum II). Cancer Treat Rev. 6:17–39. 1979. View Article : Google Scholar : PubMed/NCBI
26	Lebwohl D and Canetta R: Clinical development of platinum complexes in cancer therapy: An historical perspective and an update. Eur J Cancer. 34:1522–1534. 1998. View Article : Google Scholar : PubMed/NCBI
27	Galanski M: Recent developments in the field of anticancer platinum complexes. Recent Pat Anticancer Drug Discov. 1:285–295. 2006. View Article : Google Scholar : PubMed/NCBI
28	Siddik ZH: Cisplatin: Mode of cytotoxic action and molecular basis of resistance. Oncogene. 22:7265–7279. 2003. View Article : Google Scholar : PubMed/NCBI
29	Hueber PA, Waters P, Clark P, Clarke P, Eccles M and Goodyer P: PAX2 inactivation enhances cisplatin-induced apoptosis in renal carcinoma cells. Kidney Int. 69:1139–1145. 2006. View Article : Google Scholar : PubMed/NCBI
30	Liu W, Chen H, Wong N, Haynes W, Baker CM and Wang X: Pseudohypoxia induced by miR-126 deactivation promotes migration and therapeutic resistance in renal cell carcinoma. Cancer Lett. 394:65–75. 2017. View Article : Google Scholar : PubMed/NCBI
31	Yan L, Ding B, Liu H, Zhang Y, Zeng J, Hu J, Yao W, Yu G, An R, Chen Z, et al: Inhibition of SMYD2 suppresses tumor progression by down-regulating microRNA-125b and attenuates multi-drug resistance in renal cell carcinoma. Theranostics. 9:8377–8391. 2019. View Article : Google Scholar : PubMed/NCBI
32	Bai L, Lin G, Sun L, Liu Y, Huang X, Cao C, Guo Y and Xie C: Upregulation of SIRT6 predicts poor prognosis and promotes metastasis of non-small cell lung cancer via the ERK1/2/MMP9 pathway. Oncotarget. 7:40377–40386. 2016. View Article : Google Scholar : PubMed/NCBI
33	Azuma Y, Yokobori T, Mogi A, Altan B, Yajima T, Kosaka T, Onozato R, Yamaki E, Asao T, Nishiyama M and Kuwano H: SIRT6 expression is associated with poor prognosis and chemosensitivity in patients with non-small cell lung cancer. J Surg Oncol. 112:231–237. 2015. View Article : Google Scholar : PubMed/NCBI
34	Strub T, Ghiraldini FG, Carcamo S, Li M, Wroblewska A, Singh R, Goldberg MS, Hasson D, Wang Z, Gallagher SJ, et al: SIRT6 haploinsufficiency induces BRAF melanoma cell resistance to MAPK inhibitors via IGF signalling. Nat Commun. 9:34402018. View Article : Google Scholar : PubMed/NCBI
35	Xu L, Lin X, Zheng Y and Zhou H: Silencing of heat shock protein 27 increases the radiosensitivity of non-small cell lung carcinoma cells. Mol Med Rep. 20:613–621. 2019.PubMed/NCBI
36	Chrysovergis A, Papanikolaou VS, Tsiambas E, Ragos V, Peschos D and Kyrodimos E: Digital Analysis of BCL2 expression in laryngeal squamous cell carcinoma. Anticancer Res. 39:1253–1257. 2019. View Article : Google Scholar : PubMed/NCBI
37	Li H, Wang H, Deng K, Han W, Hong B and Lin W: The ratio of Bcl-2/Bim as a predictor of cisplatin response provides a rational combination of ABT-263 with cisplatin or radiation in small cell lung cancer. Cancer Biomark. 24:51–59. 2019. View Article : Google Scholar : PubMed/NCBI
38	Zha H, Aimé-Sempé C, Sato T and Reed JC: Proapoptotic protein Bax heterodimerizes with Bcl-2 and homodimerizes with Bax via a novel domain (BH3) distinct from BH1 and BH2. J Biol Chemistry. 271:7440–7444. 1996. View Article : Google Scholar
39	Reed JC, Zha H, Aime-Sempe C, Takayama S and Wang HG: Structure-function analysis of Bcl-2 family proteins. Regulators of programmed cell death. Adv Exp Med Biol. 406:99–112. 1996. View Article : Google Scholar : PubMed/NCBI